Nilla Avanzi

2.7k total citations
27 papers, 778 citations indexed

About

Nilla Avanzi is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Nilla Avanzi has authored 27 papers receiving a total of 778 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 11 papers in Oncology and 6 papers in Organic Chemistry. Recurrent topics in Nilla Avanzi's work include Cancer-related Molecular Pathways (5 papers), Lung Cancer Treatments and Mutations (4 papers) and Stress Responses and Cortisol (3 papers). Nilla Avanzi is often cited by papers focused on Cancer-related Molecular Pathways (5 papers), Lung Cancer Treatments and Mutations (4 papers) and Stress Responses and Cortisol (3 papers). Nilla Avanzi collaborates with scholars based in Italy, Japan and United States. Nilla Avanzi's co-authors include Antonella Isacchi, Jérôme Breton, Luisa Rusconi, Arturo Galvani, J. A. Bertrand, R Bossi, Elena Ardini, Daniele Donati, Maria Menichincheri and Paolo Orsini and has published in prestigious journals such as Journal of Molecular Biology, Biochemistry and Cancer Research.

In The Last Decade

Nilla Avanzi

26 papers receiving 760 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nilla Avanzi Italy 15 459 263 139 120 117 27 778
Gary E. Schiltz United States 18 910 2.0× 306 1.2× 135 1.0× 265 2.2× 67 0.6× 52 1.5k
Zhilin Zou China 10 560 1.2× 227 0.9× 133 1.0× 86 0.7× 45 0.4× 24 901
Jos de Man Netherlands 13 262 0.6× 122 0.5× 56 0.4× 50 0.4× 64 0.5× 22 497
Puranik Purushottamachar United States 18 669 1.5× 145 0.6× 285 2.1× 165 1.4× 34 0.3× 45 1.0k
Yasmine Kanaan United States 16 359 0.8× 177 0.7× 77 0.6× 47 0.4× 48 0.4× 46 695
Lorenza Sisinni Italy 20 637 1.4× 159 0.6× 68 0.5× 35 0.3× 267 2.3× 29 888
David Meininger United States 19 689 1.5× 124 0.5× 45 0.3× 41 0.3× 115 1.0× 22 1.2k
Ana Isabel Hernández Spain 18 492 1.1× 96 0.4× 68 0.5× 138 1.1× 26 0.2× 28 828
Sukhamoy Gorai India 16 573 1.2× 169 0.6× 38 0.3× 107 0.9× 55 0.5× 41 859
Frankis Almaguel United States 10 347 0.8× 286 1.1× 73 0.5× 63 0.5× 22 0.2× 23 757

Countries citing papers authored by Nilla Avanzi

Since Specialization
Citations

This map shows the geographic impact of Nilla Avanzi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nilla Avanzi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nilla Avanzi more than expected).

Fields of papers citing papers by Nilla Avanzi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nilla Avanzi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nilla Avanzi. The network helps show where Nilla Avanzi may publish in the future.

Co-authorship network of co-authors of Nilla Avanzi

This figure shows the co-authorship network connecting the top 25 collaborators of Nilla Avanzi. A scholar is included among the top collaborators of Nilla Avanzi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nilla Avanzi. Nilla Avanzi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Perrera, Claudia, Maurizio Pulici, Patrizia Banfi, et al.. (2023). Abstract 1615: NMS-812, a novel potent PERK inhibitor that also inhibits GCN2, exhibits strong anti-tumor activity as single agent and in combination in preclinical models. Cancer Research. 83(7_Supplement). 1615–1615. 3 indexed citations
2.
Casuscelli, Francesco, Elena Ardini, Nilla Avanzi, et al.. (2022). Stereoselective synthesis of 3,4‐dihydropyrrolo[1,2‐a]pyrazin‐1(2H)‐one derivatives as PIM kinase inhibitors inspired from marine alkaloids. Chirality. 34(11). 1437–1452. 3 indexed citations
3.
Deutsch, Melanie, Christopher S. Graffeo, Rae S. Rokosh, et al.. (2015). Divergent effects of RIP1 or RIP3 blockade in murine models of acute liver injury. Cell Death and Disease. 6(5). e1759–e1759. 99 indexed citations
4.
Brasca, Maria Gabriella, Paola Gnocchi, M. Nesi, et al.. (2015). Novel pyrrole carboxamide inhibitors of JAK2 as potential treatment of myeloproliferative disorders. Bioorganic & Medicinal Chemistry. 23(10). 2387–2407. 17 indexed citations
5.
Papeo, Gianluca, Nilla Avanzi, Serena Bettoni, et al.. (2014). Insights into PARP Inhibitors’ Selectivity Using Fluorescence Polarization and Surface Plasmon Resonance Binding Assays. SLAS DISCOVERY. 19(8). 1212–1219. 18 indexed citations
6.
Sancineto, Luca, Nunzio Iraci, Serena Massari, et al.. (2013). Computer‐Aided Design, Synthesis and Validation of 2‐Phenylquinazolinone Fragments as CDK9 Inhibitors with Anti‐HIV‐1 Tat‐Mediated Transcription Activity. ChemMedChem. 8(12). 1941–1953. 29 indexed citations
7.
Casuscelli, Francesco, Elena Ardini, Nilla Avanzi, et al.. (2013). Discovery and optimization of pyrrolo[1,2-a]pyrazinones leads to novel and selective inhibitors of PIM kinases. Bioorganic & Medicinal Chemistry. 21(23). 7364–7380. 28 indexed citations
8.
Ardini, Elena, Maria Menichincheri, Patrizia Banfi, et al.. (2013). Abstract 2092: The ALK inhibitor NMS-E628 also potently inhibits ROS1 and induces tumor regression in ROS-driven models .. Cancer Research. 73(8_Supplement). 2092–2092. 9 indexed citations
9.
10.
Felder, Eduard, Sergio Mantegani, Christian Orrenius, et al.. (2012). The generation of purinome-targeted libraries as a means to diversify ATP-mimetic chemical classes for lead finding. Molecular Diversity. 16(1). 27–51. 8 indexed citations
11.
Colombo, Riccardo, Marina Caldarelli, Maria Laura Giorgini, et al.. (2012). 517 NMS-P153, a Tight-Binder Inhibitor of the Spindle Assembly Checkpoint Kinase MPS1. European Journal of Cancer. 48. 159–159.
12.
Ardini, Elena, Maria Menichincheri, Patrizia Banfi, et al.. (2011). In vitro and in vivo activity of NMS-E628 against ALK mutations resistant to Xalkori.. 9 indexed citations
13.
Albanese, Clara, Rachele Alzani, Nadia Amboldi, et al.. (2010). Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor Efficacy. Molecular Cancer Therapeutics. 9(8). 2243–2254. 51 indexed citations
14.
Colombo, Riccardo, Marina Caldarelli, Milena Mennecozzi, et al.. (2010). Targeting the Mitotic Checkpoint for Cancer Therapy with NMS-P715, an Inhibitor of MPS1 Kinase. Cancer Research. 70(24). 10255–10264. 129 indexed citations
15.
Bossi, R, Maria Beatrice Saccardo, Elena Ardini, et al.. (2010). Crystal Structures of Anaplastic Lymphoma Kinase in Complex with ATP Competitive Inhibitors. Biochemistry. 49(32). 6813–6825. 126 indexed citations
16.
Breton, Jérôme, Nilla Avanzi, Simona Magagnin, et al.. (2000). Functional characterization and mechanism of action of recombinant human kynurenine 3‐hydroxylase. European Journal of Biochemistry. 267(4). 1092–1099. 59 indexed citations
17.
Toma, Salvatore, Masayuki Nakamura, Shigenobu Toné, et al.. (1997). Cloning and recombinant expression of rat and human kynureninase. FEBS Letters. 408(1). 5–10. 20 indexed citations
18.
Mosca, M., Liviana Cozzi, Jérôme Breton, et al.. (1996). Cloning of Rat and Human Kynurenine Aminotransferase. Advances in experimental medicine and biology. 398. 449–454. 9 indexed citations
19.
Breton, Jérôme, Nilla Avanzi, Barbara Valsasina, et al.. (1995). Detection of traces of a trisulphide derivative in the preparation of a recombinant truncated interleukin-6 mutein. Journal of Chromatography A. 709(1). 135–146. 25 indexed citations
20.
Valenti, Piero, et al.. (1985). Xanthone Analogue of Geiparvarin. Archiv der Pharmazie. 318(10). 923–926. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gary E. Schiltz Breakdown of academic impact, for papers by Zhilin Zou Breakdown of academic impact, for papers by Jos de Man Breakdown of academic impact, for papers by Puranik Purushottamachar Breakdown of academic impact, for papers by Yasmine Kanaan Breakdown of academic impact, for papers by Lorenza Sisinni Breakdown of academic impact, for papers by David Meininger Breakdown of academic impact, for papers by Ana Isabel Hernández Breakdown of academic impact, for papers by Sukhamoy Gorai Breakdown of academic impact, for papers by Frankis Almaguel
Rankless by CCL
2026